# Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial

> **NCT05200936** · PHASE2 · COMPLETED · sponsor: **Definium Therapeutics US, Inc.** · enrollment: 53 (actual)

## Conditions studied

- ADHD
- Attention Deficit Disorder

## Interventions

- **DRUG:** MM120
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05200936
- **Lead sponsor:** Definium Therapeutics US, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-17
- **Primary completion:** 2023-11-06
- **Final completion:** 2023-12-04
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05200936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05200936, "Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05200936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*